Dr. Renuka Iyer Appointed as New Chief Medical Officer of NCCN

New Leadership at NCCN

The National Comprehensive Cancer Network® (NCCN®) has announced the appointment of Dr. Renuka Iyer as its new Chief Medical Officer (CMO). This significant move comes as the NCCN seeks to enhance its commitment to developing gold-standard cancer treatment guidelines and improving patient care globally. With her extensive experience in oncology and her role at Roswell Park Comprehensive Cancer Center, Dr. Iyer is poised to lead initiatives that could redefine cancer treatment protocols.

Background of Dr. Renuka Iyer

Dr. Iyer is no stranger to the world of oncology. Serving as a professor and leading a division of gastrointestinal oncology, she brings a wealth of knowledge and leadership to her new role. Her academic achievements include a medical degree from Grant Medical College, post-graduate training at the University of Buffalo, and a residency at Weill Cornell Medical College. Dr. Iyer is board-certified in internal medicine and oncology, which bolsters her qualifications as she steps into this pivotal position.

Her notable accolades come from numerous esteemed organizations like the American Society of Clinical Oncology and the Cholangiocarcinoma Foundation, marking her as a respected figure in the field. Additionally, her contributions to research and clinical practices include the development of innovative therapies for rare cancers and a focus on immunotherapy, enhancing both the quality of life and clinical outcomes for patients.

Commitment to Quality Cancer Care

Dr. Crystal S. Denlinger, the CEO of NCCN, stated, “Renuka is the ideal candidate to take on this vital role impacting cancer treatment and outcomes globally.” Emphasizing Dr. Iyer’s longstanding commitment to advancing research and patient care, Denlinger expressed confidence in her ability to implement meaningful changes. Dr. Iyer’s longstanding involvement with NCCN, including her role on the NCCN Guidelines Steering Committee, showcases her understanding of the organization’s mission to provide evidence-based guidelines.

The NCCN provides detailed guidelines that cater to almost every type of cancer treatment, emphasizing the importance of regular updates, often more than annually, to incorporate the latest research and therapies.

Expectations and Future Initiatives

As the new CMO, Dr. Iyer will play a crucial role in overseeing the NCCN Guidelines program and ensuring that the organization continues to lead in the field of oncology. Her duties will encompass supervising clinical resources based on NCCN Guidelines and directing the department of Continuing Education (CE) within the organization.

“I am honored to have been selected for this prestigious position,” Dr. Iyer expressed. “After spending 21 years in academic oncology, I am excited to drive high-quality cancer care forward and to build bridges that further NCCN's mission.”

As Dr. Iyer prepares for her first day on February 26, 2026, the oncology community looks forward to her leadership and the innovations she will bring to enhance cancer treatment standards. The NCCN, celebrating its 30th anniversary, remains dedicated to providing clear, evidence-based, and accessible oncology care for patients, emphasizing their mission to ensure better health outcomes through quality cancer prevention, treatment, and education.

For more information, please visit NCCN.org.